Sales of key cystic fibrosis drugs are projected to rise across the US and Europe from some $2.6bn in 2016 to $7.2bn in 2025 due to strong demand for high-cost CFTR modulator therapies as patient populations expand and life expectancies improve. Vertex Pharmaceuticals Inc.’s investigational VX-661/ivacaftor combo is likely to lead the pack, according to a new report by Informa’s Datamonitor Healthcare.
Vertex’s investigational CFTR corrector/potentiator combination therapy VX-661/ivacaftor, currently in Phase III trials, looks set to be successful and ride a rising wave of demand for novel cystic fibrosis therapies, according to the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?